• Kymera Therapeutics Inc KYMR.OQ reported a quarterly adjusted loss of 88 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of twenty analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from $-1.01 to -8 cents per share.

• Revenue fell 84.6% to $7.39 million from a year ago; analysts expected $11.82 million.

• Kymera Therapeutics Inc's reported EPS for the quarter was a loss of 88 cents​.

• The company reported a quarterly loss of $70.75 million.

• Kymera Therapeutics Inc shares had fallen by 12.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $57.00

This summary was machine generated from LSEG data February 27 at 04:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)